Zanubrutinib, such as acalabrutinib, was designed to be a more selective inhibitor of BTK, potentially providing more durable PFS than ibrutinib, including patients with TP53 aberrant CLL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.